NMN / NR
Also sold as: Nicotinamide mononucleotide · Nicotinamide riboside · NAD+ precursors
Precursors used to raise NAD+, a coenzyme involved in cellular metabolism. Human trials show target engagement more consistently than meaningful improvements in health or function.
Longevity Energy Sleep Focus
Community
Not enough ratings yet: 0 of 10
Scores appear after 10 ratings, so that one or two reports can't dominate. Tried it? Your rating counts.
Research
SleepLimited · benefitFocusNo established evidenceEnergyLimited · benefitLongevityNo established evidence
- Sleep: One 12-week study in older Japanese adults reported selected timing-dependent sleepiness/fatigue changes; replication is lacking.
- Focus: Early NR studies in neurologic disease and biomarker changes do not establish cognitive benefit in healthy adults.
- Energy: Small trials show selected exercise/fatigue signals in specific populations, without established general energy enhancement.
- Longevity: No indexed human trial establishes longer life or reduced mortality; higher NAD+ is not proof of anti-aging efficacy.
REALITY CHECK // Raising NAD+ is the clearest replicated result; it is a biomarker, not a lifespan outcome. A review covering 113 studies (33 human, 80 rodent) found heterogeneous and often null human functional outcomes, with no human lifespan/mortality trial. Form superiority and sublingual/liposomal premiums are unproven.
Levels: how we grade evidence. Grey = evidence of no benefit; amber = evidence it makes this goal worse.
Ratings are self-reported by a self-selected group of users: how it felt, not proof that it works.
Check your bottle
Compare what your label says with what was used in trials. This is a trial range, not a personal prescription.
Enter the amount from your label to see the result.
How it was studied
01 // STUDIED_DOSE_RANGE
Trial exposure, not an individual prescription
The dossier summarizes short-term oral NMN exposures of 250-2000 mg/day for up to 24 weeks; this is a broad safety-study interval, not an established effective target. Selected metabolic trials lasted about 10-12 weeks, exercise trials 6-12 weeks and the older-adult sleep/fatigue trial 12 weeks. Exact NR-specific trial mg exposures are not supplied here.
02 // TIMING_&_MATRIX
Route and formulation matter
No general superiority of sublingual/liposomal delivery is established. A selected older-adult trial studied timing; molecule identity and separate NR/NMN mass remain essential.
03 // EVALUATION_WINDOW
Match the study window
Exercise/function trials generally 6-12 weeks, metabolic trials about 10-12 weeks, sleep/fatigue 12 weeks; short-term safety data extend to about 24 weeks. No lifespan trial.
04 // SAFETY_&_QUALITY_GATE
Clinical review and label check
Pregnancy, lactation and children lack adequate safety data. With active cancer or cancer treatment, discuss use with an oncologist: effects on tumor metabolism are unresolved, largely theoretical/preclinical. Long-term safety beyond about six months remains uncertain. Short-term trials reporting no increase in adverse events do not prove indefinite safety.
UPPER LIMIT // No comparable formal EFSA/NIH UL is verified for NMN or NR. Short-term trial tolerability at 250-2000 mg/day does not establish a lifetime safety ceiling or replace product-specific regulatory conditions.
Summary
NR and NMN can raise NAD+, but clinical metabolic and functional results are often null or population-specific. A narrow positive muscle-insulin-sensitivity trial must be weighed against largely null metabolic meta-analyses. Human lifespan extension is untested, not demonstrated.
Mechanism
NR/NMN feed NAD+ salvage pathways used in redox metabolism and by enzymes such as sirtuins/PARPs. Whether intact oral NMN transport or prior breakdown dominates in humans is unsettled; mouse transporter findings do not prove human superiority.
Typical studied dose
The dossier summarizes short-term oral NMN exposures of 250-2000 mg/day for up to 24 weeks; this is a broad safety-study interval, not an established effective target. Selected metabolic trials lasted about 10-12 weeks, exercise trials 6-12 weeks and the older-adult sleep/fatigue trial 12 weeks. Exact NR-specific trial mg exposures are not supplied here.
Upper limit
No comparable formal EFSA/NIH UL is verified for NMN or NR. Short-term trial tolerability at 250-2000 mg/day does not establish a lifetime safety ceiling or replace product-specific regulatory conditions.
Popular stacks with NMN / NR
Not enough stack data yet. A combination with NMN / NR appears here once 5 people rate the same set.
Forms and label traps
| Form on label | Active content | Studied range / day | Absorption & GI tolerance | Verdict |
|---|---|---|---|---|
| Nicotinamide riboside chloride Best for: Identifying a well-studied NAD+ precursor, not proven longevity treatment. |
Unstandardized: active content unknown | no comparable trial range | Human studies show NAD+ increases; obese-men insulin-sensitivity results were null. Generally tolerated over short trials. |
Studied standard [FORM // REFERENCE] Exact NR-specific trial mass is unavailable in this extraction. No percentage/absorption conversion is justified. |
| Beta-nicotinamide mononucleotide Best for: Comparing whole NMN mass with the broad studied safety interval. |
Extract weight · marker not quantified | 250–2000 mg | Human NAD+ increases are reported, but intact transport versus breakdown remains unsettled. Generally tolerated in short-term studies. |
Good option [FORM // GOOD] 250-2000 mg/day spans different populations and endpoints; it is not an established effective longevity range. Full compound mass, not an invented marker percentage. |
| Sublingual / liposomal NMN or NR Best for: Checking claims and price premiums. |
Unstandardized: active content unknown | no comparable trial range | No robust comparative human PK evidence for a meaningful superiority is indexed. No established tolerability advantage. |
Caution [FORM // CAUTION] No justified mg-equivalence or superior human clinical outcome can be calculated. |
| Nicotinamide / nicotinic acid alternatives Best for: Recognizing molecule identity rather than treating all vitamin B3 forms alike. |
Unstandardized: active content unknown | no comparable trial range | Other NAD+ precursors have different metabolic and tolerability profiles; they are not interchangeable. Nicotinic acid can cause flushing; high-dose compounds carry separate risks. |
Caution [FORM // CAUTION] The head-to-head catalog title supports a comparison of three boosters, not universal equivalence or a generic mg target. |
Common label traps
- TRAP_01 // HIGHER NAD+ MEANS LONGER LIFE
Human NAD+ engagement does not establish reduced mortality or reversal of aging. Lifespan findings are chiefly rodent data. - TRAP_02 // NMN ALWAYS BEATS NR, OR NR ALWAYS BEATS NMN
Direct human comparisons are sparse; no general superiority is established. - TRAP_03 // LIPOSOMAL OR SUBLINGUAL MEANS MUCH MORE EFFECTIVE
Comparative human PK/clinical evidence is inadequate to justify a conversion or efficacy premium. - TRAP_04 // COMPLETELY SAFE / DEFINITELY FEEDS CANCER
Both claims overstate evidence. Short-term tolerability is not long-term safety, and tumor-metabolism concerns are unresolved in humans.
Other outcomes studied
Outside the five leaderboard goals. Same evidence levels as above.
- NAD+ biomarker engagement Strong · benefit
NR/NMN generally raise blood/PBMC NAD+ in middle-aged/older adults. Some trials differ by compartment and assay; this is target engagement, not a health outcome.
PMID 29599478 PMID 36482258 PMID 41540253 PMID 39116016 - Glucose and lipid metabolism Limited · no benefit
A roughly 25-person trial in overweight postmenopausal women with prediabetes improved muscle insulin sensitivity. Pooled fasting glucose/HbA1c/lipid results were largely null; NR in obese men did not improve insulin sensitivity. The narrow positive result cannot be generalized.
PMID 33888596 PMID 39116016 PMID 42514320 PMID 29992272 - Muscle mass and function Limited · no benefit
Meta-analysis in older adults aged about 60.9-83: muscle-mass index MD -0.42 (95% CI -0.99 to 0.14), p=0.14; grip-strength p=0.42/0.56; gait-speed MD -0.01, p=0.79. No meaningful pooled benefit was demonstrated.
PMID 40275690 PMID 39185644 - Exercise capacity / walking Limited · benefit
Small trials report selected oxygen-use/ventilatory-threshold changes in mainly male amateur runners, not peak VO2max, and walking/function signals in specific older populations. The six-minute-walk trial had manufacturer sponsorship.
PMID 34238308 PMID 36482258 PMID 36443648 - Sleepiness and fatigue Limited · benefit
One 12-week RCT in older Japanese adults reported selected fatigue/sleepiness and lower-limb-function changes depending on afternoon timing; no broad sleep cure is established.
PMID 35215405 - Vascular markers Limited · benefit
Small/subgroup blood-pressure and arterial-stiffness signals are mixed; NR plus exercise pilot results do not establish prevention of cardiovascular events.
PMID 36797393 PMID 42514320 PMID 40770531 PMID 29599478 - Neurologic disease / cognition Limited · benefit
Early NR trials in MCI/Parkinson disease and neuronal-origin plasma-vesicle biomarkers indicate mechanistic signals; no established benefit for cognition in healthy adults or prevention of neurodegeneration.
PMID 39422945 PMID 42478598 PMID 35235774 PMID 36515353 - Oocyte quality No established evidence
Systematic review/transcriptomic evidence is mainly mouse/in-vitro; no established clinical live-birth benefit.
PMID 41160202 - Human lifespan / anti-aging No established evidence
The systematic review covered 113 studies: 33 human and 80 rodent. Human results were heterogeneous/often null, and no human study assessed lifespan or mortality; no human lifespan benefit is established.
PMID 41655607 PMID 31917996 - Werner syndrome: NR Limited · benefit
A small crossover RCT reports benefits in a rare genetic premature-aging syndrome; this does not establish anti-aging efficacy in healthy people.
PMID 40459998 - Short-term safety Limited · no benefit
At 250-2000 mg/day for up to 24 weeks, pooled trials reported no increase in adverse/serious events, withdrawals or significant ALT/AST elevation. This safety finding is not an efficacy benefit or long-term guarantee.
PMID 42514320
Reader questions
Do NMN and NR actually work?
They usually raise NAD+. Clinical glucose, muscle and function results are much less consistent, and no human lifespan extension has been demonstrated.
Which is better: NMN or NR?
Human head-to-head evidence is sparse. Neither can be declared the universal winner; formulation marketing is stronger than comparative clinical data.
Morning or afternoon?
An older-adult trial found selected afternoon-dependent outcomes. It does not establish an optimal schedule for everyone.
Can I use one during cancer treatment?
Only after discussion with the treating oncologist. Tumor-metabolism concerns are unresolved in humans and are not grounds for independent treatment decisions.
What is its current legal status?
Regulatory status can vary by jurisdiction and time. The dossier contains inconsistent regulatory assertions, so current authorization must be checked independently before publication or purchase.
Do I need TMG or other NAD+ boosters with it?
Methyl-donor and combination arguments are mechanistic; the dossier does not establish a necessary supplement stack or additive clinical benefit.
Stack interactions
- Caution Antidiabetic medication [CAUTION // REVIEW_CONTEXT]
One narrow trial showed increased muscle insulin sensitivity; additive hypoglycemia is theoretical, while pooled metabolic results are predominantly null.
PMID 33888596 - Caution Immunosuppressants / autoimmune disease [CAUTION // REVIEW_CONTEXT]
NAD+-immune/Th17 signaling is a mechanistic reason for review, not a proven clinically important drug interaction.
PMID 42048163 - Caution Other NAD+ precursors [CAUTION // REVIEW_CONTEXT]
Combining NR, NMN and nicotinamide has no established additive healthy-population benefit; it complicates exposure and cost. - Caution Resveratrol, pterostilbene, TMG or CoQ10 [CAUTION // REVIEW_CONTEXT]
Sirtuin/substrate, methyl-donor and mitochondrial arguments are mechanistic; no general clinical synergy is demonstrated here. Separate compound doses matter.
Red flags: interactions and who should avoid it
Interactions
Potential additive glucose effects with antidiabetic drugs are theoretical despite one population-specific positive trial; pooled metabolic effects are mostly null. NAD+-immune signaling creates a theoretical immunosuppressant/autoimmune interaction, not an established clinical interaction. Multiple NAD+ precursors, resveratrol/pterostilbene, TMG and CoQ10 have no established general healthy-population synergy.
Avoid or ask a doctor first if
Pregnancy, lactation and children lack adequate safety data. With active cancer or cancer treatment, discuss use with an oncologist: effects on tumor metabolism are unresolved, largely theoretical/preclinical. Long-term safety beyond about six months remains uncertain. Short-term trials reporting no increase in adverse events do not prove indefinite safety.
Sources (PubMed, 23)
- Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults.
PMID 29599478 · 2018 · Randomized controlled trialNR/NMN generally raise blood/PBMC NAD+ in middle-aged/older adults. Some trials differ by compartment and assay; this is target engagement, not a health outcome. Small/subgroup blood-pressure and arterial-stiffness signals are mixed; NR plus exercise pilot results do not establish prevention of cardiovascular events. Human studies show NAD+ increases; obese-men insulin-sensitivity results were null. Exact NR-specific trial mass is unavailable in this extraction. No percentage/absorption conversion is justified.
- The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial.
PMID 36482258 · 2023 · Randomized controlled trialNR/NMN generally raise blood/PBMC NAD+ in middle-aged/older adults. Some trials differ by compartment and assay; this is target engagement, not a health outcome. Small trials report selected oxygen-use/ventilatory-threshold changes in mainly male amateur runners, not peak VO2max, and walking/function signals in specific older populations. The six-minute-walk trial had manufacturer sponsorship. Human NAD+ increases are reported, but intact transport versus breakdown remains unsettled. 250-2000 mg/day spans different populations and endpoints; it is not an established effective longevity range. Full compound mass, not an invented marker percentage.
- The differential impact of three different NAD+ boosters on circulatory NAD and microbial metabolism in humans.
PMID 41540253 · 2026 · Randomized controlled trialNR/NMN generally raise blood/PBMC NAD+ in middle-aged/older adults. Some trials differ by compartment and assay; this is target engagement, not a health outcome. Human NAD+ increases are reported, but intact transport versus breakdown remains unsettled. 250-2000 mg/day spans different populations and endpoints; it is not an established effective longevity range. Full compound mass, not an invented marker percentage. Other NAD+ precursors have different metabolic and tolerability profiles; they are not interchangeable. The head-to-head catalog title supports a comparison of three boosters, not universal equivalence or a generic mg target.
- Efficacy of oral nicotinamide mononucleotide supplementation on glucose and lipid metabolism for adults: a systematic review with meta-analysis on randomized controlled trials.
PMID 39116016 · 2025 · Systematic review and meta-analysisNR/NMN generally raise blood/PBMC NAD+ in middle-aged/older adults. Some trials differ by compartment and assay; this is target engagement, not a health outcome. A roughly 25-person trial in overweight postmenopausal women with prediabetes improved muscle insulin sensitivity. Pooled fasting glucose/HbA1c/lipid results were largely null; NR in obese men did not improve insulin sensitivity. The narrow positive result cannot be generalized.
- Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women.
PMID 33888596 · 2021 · Randomized controlled trialA roughly 25-person trial in overweight postmenopausal women with prediabetes improved muscle insulin sensitivity. Pooled fasting glucose/HbA1c/lipid results were largely null; NR in obese men did not improve insulin sensitivity. The narrow positive result cannot be generalized. Human NAD+ increases are reported, but intact transport versus breakdown remains unsettled. 250-2000 mg/day spans different populations and endpoints; it is not an established effective longevity range. Full compound mass, not an invented marker percentage. One narrow trial showed increased muscle insulin sensitivity; additive hypoglycemia is theoretical, while pooled metabolic results are predominantly null.
- Safety and Metabolism-Related Outcomes of Oral Nicotinamide Mononucleotide Supplementation in Adults: A Systematic Review and Meta-Analysis.
PMID 42514320 · 2026 · Systematic review and meta-analysisA roughly 25-person trial in overweight postmenopausal women with prediabetes improved muscle insulin sensitivity. Pooled fasting glucose/HbA1c/lipid results were largely null; NR in obese men did not improve insulin sensitivity. The narrow positive result cannot be generalized. Small/subgroup blood-pressure and arterial-stiffness signals are mixed; NR plus exercise pilot results do not establish prevention of cardiovascular events. At 250-2000 mg/day for up to 24 weeks, pooled trials reported no increase in adverse/serious events, withdrawals or significant ALT/AST elevation. This safety finding is not an efficacy benefit or long-term guarantee.
- A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects.
PMID 29992272 · 2018 · Randomized controlled trialA roughly 25-person trial in overweight postmenopausal women with prediabetes improved muscle insulin sensitivity. Pooled fasting glucose/HbA1c/lipid results were largely null; NR in obese men did not improve insulin sensitivity. The narrow positive result cannot be generalized. Human studies show NAD+ increases; obese-men insulin-sensitivity results were null. Exact NR-specific trial mass is unavailable in this extraction. No percentage/absorption conversion is justified.
- The Effect of Nicotinamide Mononucleotide and Riboside on Skeletal Muscle Mass and Function: A Systematic Review and Meta-Analysis.
PMID 40275690 · 2025 · Systematic review and meta-analysisMeta-analysis in older adults aged about 60.9-83: muscle-mass index MD -0.42 (95% CI -0.99 to 0.14), p=0.14; grip-strength p=0.42/0.56; gait-speed MD -0.01, p=0.79. No meaningful pooled benefit was demonstrated.
- Effects of Nicotinamide Mononucleotide Supplementation on Muscle and Liver Functions Among the Middle-aged and Elderly: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
PMID 39185644 · 2025 · Systematic review and meta-analysisMeta-analysis in older adults aged about 60.9-83: muscle-mass index MD -0.42 (95% CI -0.99 to 0.14), p=0.14; grip-strength p=0.42/0.56; gait-speed MD -0.01, p=0.79. No meaningful pooled benefit was demonstrated.
- Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study.
PMID 34238308 · 2021 · Randomized controlled trialSmall trials report selected oxygen-use/ventilatory-threshold changes in mainly male amateur runners, not peak VO2max, and walking/function signals in specific older populations. The six-minute-walk trial had manufacturer sponsorship.
- Effects of nicotinamide mononucleotide on older patients with diabetes and impaired physical performance: A prospective, placebo-controlled, double-blind study.
PMID 36443648 · 2023 · Randomized controlled trialSmall trials report selected oxygen-use/ventilatory-threshold changes in mainly male amateur runners, not peak VO2max, and walking/function signals in specific older populations. The six-minute-walk trial had manufacturer sponsorship.
- Effect of 12-Week Intake of Nicotinamide Mononucleotide on Sleep Quality, Fatigue, and Physical Performance in Older Japanese Adults: A Randomized, Double-Blind Placebo-Controlled Study.
PMID 35215405 · 2022 · Randomized controlled trialOne 12-week RCT in older Japanese adults reported selected fatigue/sleepiness and lower-limb-function changes depending on afternoon timing; no broad sleep cure is established.
- Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial.
PMID 36797393 · 2023 · Randomized controlled trialSmall/subgroup blood-pressure and arterial-stiffness signals are mixed; NR plus exercise pilot results do not establish prevention of cardiovascular events.
- Nicotinamide riboside combined with exercise to treat hypertension in middle-aged and older adults: a pilot randomized clinical trial.
PMID 40770531 · 2025 · Randomized controlled trialSmall/subgroup blood-pressure and arterial-stiffness signals are mixed; NR plus exercise pilot results do not establish prevention of cardiovascular events.
- Supplementation with NAD+ Precursors for Treating Alzheimer's Disease: A Metabolic Approach.
PMID 39422945 · 2024 · Systematic review and meta-analysisEarly NR trials in MCI/Parkinson disease and neuronal-origin plasma-vesicle biomarkers indicate mechanistic signals; no established benefit for cognition in healthy adults or prevention of neurodegeneration.
- A phase-II randomized controlled pilot study of nicotinamide riboside supplementation in older adults with amnestic mild cognitive impairment.
PMID 42478598 · 2026 · Randomized controlled trialEarly NR trials in MCI/Parkinson disease and neuronal-origin plasma-vesicle biomarkers indicate mechanistic signals; no established benefit for cognition in healthy adults or prevention of neurodegeneration.
- The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease.
PMID 35235774 · 2022 · Randomized controlled trialEarly NR trials in MCI/Parkinson disease and neuronal-origin plasma-vesicle biomarkers indicate mechanistic signals; no established benefit for cognition in healthy adults or prevention of neurodegeneration.
- Oral nicotinamide riboside raises NAD+ and lowers biomarkers of neurodegenerative pathology in plasma extracellular vesicles enriched for neuronal origin.
PMID 36515353 · 2023 · Randomized controlled trialEarly NR trials in MCI/Parkinson disease and neuronal-origin plasma-vesicle biomarkers indicate mechanistic signals; no established benefit for cognition in healthy adults or prevention of neurodegeneration.
- NMN supplementation as a strategy to improve oocyte quality: a systematic review and transcriptomic analysis.
PMID 41160202 · 2026 · Systematic review and meta-analysisSystematic review/transcriptomic evidence is mainly mouse/in-vitro; no established clinical live-birth benefit.
- NAD⁺ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence.
PMID 41655607 · 2026 · Systematic review and meta-analysisThe systematic review covered 113 studies: 33 human and 80 rodent. Human results were heterogeneous/often null, and no human study assessed lifespan or mortality; no human lifespan benefit is established.
- NAD+ therapy in age-related degenerative disorders: A benefit/risk analysis.
PMID 31917996 · 2020 · Systematic review and meta-analysisThe systematic review covered 113 studies: 33 human and 80 rodent. Human results were heterogeneous/often null, and no human study assessed lifespan or mortality; no human lifespan benefit is established.
- Nicotinamide Riboside Supplementation Benefits in Patients With Werner Syndrome: A Double-Blind Randomized Crossover Placebo-Controlled Trial.
PMID 40459998 · 2025 · Randomized controlled trialA small crossover RCT reports benefits in a rare genetic premature-aging syndrome; this does not establish anti-aging efficacy in healthy people.
- NAD+ augmentation by nicotinamide riboside engages SLIT2/ROBO1 signaling to attenuate Th17 inflammation in psoriasis.
PMID 42048163 · 2026 · Randomized controlled trialNAD+-immune/Th17 signaling is a mechanistic reason for review, not a proven clinically important drug interaction.
Community comments
No approved comments yet. Comments are held for moderation.